Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF0PI8
|
|||
| Drug Name |
BAY 1817080
|
|||
| Synonyms |
Eliapixant
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cough [ICD-11: MD12; ICD-10: R05] | Phase 1 | [1] | |
| Endometriosis [ICD-11: GA10; ICD-10: N80, N80.9] | Phase 1 | [1] | ||
| Company |
Bayer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2X purinoceptor 3 (P2RX3) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04471337) Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function. U.S. National Institutes of Health. | |||
| REF 2 | Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.